Healthcare

Echo IQ Limited (ASX:EIQ) has emerged as a transformative force in healthcare diagnostics, leveraging artificial intelligence to revolutionize cardiac imaging analysis. Trading at $0.72 per share with a recent 17.07% surge, the company commands a market capitalization of approximately $404.81 million. The substantial upward …

For investors tracking Radiopharm Theranostics stock analysis and RAD share price outlook, this data matters. TheASXandNASDAQ-listed biotech has moved from relative obscurity into the investment spotlight because it's solving a genuine clinical problem: improving diagnostics for a patient population measured in hundreds of thousands.

The company's pilot data demonstrates clinical efficacy well beyond regulatory thresholds, with leading U.S. medical institutions now enrolling patients. For investors interested in digital health innovation and emerging diagnostics, BlinkLab represents a compelling risk-reward proposition as it approaches a critical regulatory inflection point.

Emyria Limited (ASX:EMD)is anAustralianhealthcare and mental health innovation company developingpsychedelic-assisted therapiesand other novel treatments for treatment-resistant mental health conditions. Its integrated business model combinesclinical service delivery, real-world patient data, and therapy/drug development pipelines. Emyria aims to create a scalable, reimbursable framework for innovative mental …

Genetic Technologies Ltd (ASX:GTG), a long-standing player in the genetic testing and molecular diagnostics space, has once again come under investor scrutiny following a significant strategic update. The company’s announcement that it will no longer proceed with the acquisition of Ellerfield Private Wealth signals …

Recce Pharmaceuticals Ltd (ASX:RCE) has drawn renewed investor attention following the announcement of a keypatentgrant in Brazil, reinforcing its intellectual property footprint in one of the world’s largest antibiotic markets. The stock recorded a notable intraday gain of approximately 5.21% on 24 March 2026, …

As neurodevelopmental disorders including autism spectrum disorder affect millions of children globally, demand for effective, well-tolerated therapeutics remains substantially unmet. Neurotech's clinical trial data suggesting clinically meaningful benefits in ASD addresses a genuine healthcare need.